Elyan Partners to acquire a 52.17% stake in Oncodesign in a €100m deal.

Elyan Partners, a private equity firm, agreed to acquire a 52.17% stake in Oncodesign, a biopharmaceutical company, in a €100m deal. "We are delighted to be joining forces with Philippe Genne, Fabrice Viviani and the whole ONCODESIGN Service team to make ODS a European leader in Drug Discovery services. Drawing on the strength of its unique scientific expertise, its international presence and its innovative commercial approach, ODS has considerable development potential in supporting its clients – biotech and pharmaceuticals groups – in the growth of their research projects. We are keen to contribute to this creation of value through a collaborative approach to development, and most notably through the completion of targeted acquisitions,” Jean-François Félix, Vincent Manès and Maxence de Vienne, Elyan Partners.